

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

# ic acid ProductInformation

3-Guanidinopropionic acid

Product Number **G 6878** Storage Temperature -0 °C

Replacement for Product Code 39,030-5

#### **Product Description**

Molecular Formula: C<sub>4</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub> Molecular Weight: 131.1 CAS Number: 353-09-3 Melting Point: 217-218 °C<sup>1</sup>

Synonym: GPA

GPA is a physiological constituent of mammalian blood plasma, erythrocytes, brain, liver, kidney, aorta, and urine. GPA may be formed by L-arginine:glycine amidinotransferase through transamidination between arginine and  $\beta$ -alanine.

This product is one of the more commonly used creatine analogs. It has been shown to competitively inhibit creatine transport across the plasmalemma. When fed to rats and mice. GPA was shown to cause the concentrations of creatine and phosphocreatine in heart and skeletal muscle to progressively decrease over time.3 In addition to inhibiting creatine uptake, GPA and other creatine analogs appear to be transported themselves by the creatine transporter.4 Uptake was shown to be inhibited most efficiently and in a competitive manner by GPA ( $K_i = 8.8-120 \mu M$ ). Furthermore, in animals fed GPA, cyclocreatine, or homocyclocreatine, the accumulation of these creatine analogs within the tissues is paralleled by a decline in intracellular creatine and phosphocreatine concentrations.<sup>5,6</sup> Administration of GPA and other creatine analogs has, therefore, been used widely as an experimental means of depleting tissue creatine and phosphocreatine in vivo, with the final goal to unravel the physiological functions of the creatine kinase system.

This product has been demostrated to improve insulin sensitivity and to promote weight loss selectively from adipose tissue in animal models of non-insulindependent diabetes mellitus (NIDDM). Modifications such as  $\alpha$  -alkylation, homologation, and bioisosteric replacement of the aminoguanidine were shown to be detrimental to antidiabetic activity. In fact, treatment of animals with GPA has not only been shown to significantly lower body weight, but also retards growth relative to normal controls. GPA will even cause young animals to stop eating and often die.

Nevertheless, GPA feeding of rats causes an increase in the mass of brown adipose tissue as well as in DNA, glycogen, and total protein content in this tissue. At the same time, there is an impairment in thermogenic activity in the brown adipose tissue, leading to hypothermia. 10

This product has also been shown to inhibit replication of several viruses including human and simian cytomegaloviruses and varicella zoster virus, <sup>11</sup> to protect neurons from 3-NP toxicity disease, <sup>12</sup> and reduce tumor size. <sup>13</sup> A recent article reviews the potential uses of creatine analogs. <sup>14</sup>

#### **Precautions and Disclaimer**

For Laboratory Use Only. Not for drug, household or other uses.

### **Preparation Instructions**

This product is soluble in water (100 mg/ml).

## References

- 1. J. Am. Chem. Soc., 75, 3138 (1953).
- Clark, J. F., et al., Actions of the creatine analogue beta-guanidinopropionic acid on rat heart mitochondria. Biochem. J., 300(Pt. 1), 211-216 (1994).
- 3. Holtzman, D, et al., Brain creatine phosphate and creatine kinase in mice fed an analogue of creatine. Brain Res., **483(1)**, 68-77 (1989).
- Fitch, C. D., et al., Creatine metabolism in skeletal muscle. 3. Specificity of the creatine entry process. J. Biol. Chem., 243(8), 2024-2027 (1968).
- 5. Fitch, C. D., Experimental depletion of creatine and phosphocreatine from skeletal muscle. J. Biol. Chem., **249(4)**, 1060-1063 (1974).
- 6. Watanabe, Y., et al., Synthesis of neuroactive guanidino compounds by rat kidney L-arginine:glycine amidinotransferase. Life Sci., **55(5)**, 351-358 (1994).
- Vaillancourt, V. A., et al., Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid. J. Med. Chem., 44(8), 1231-1248 (2001).

- Adams, G. R., and Baldwin, K. M., Age dependence of myosin heavy chain transitions induced by creatine depletion in rat skeletal muscle. J. Appl. Physiol., 78(1), 368-371 (1995).
- Roberts, J. J., and Walker, J. B., Higher homolog and N-ethyl analog of creatine as synthetic phosphagen precursors in brain, heart, and muscle, repressors of liver amidinotransferase, and substrates for creatine catabolic enzymes. J. Biol. Chem., 260(25), 13502-13508 (1985).
- Wakatsuki, T., et al., Thermogenic responses to high-energy phosphate contents and/or hindlimb suspension in rats. Jpn. J. Physiol., 46(2), 171-175 (1996).
- Lillie, J. W., et al., Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses. Antiviral Res. 23(3-4), 203-218 (1994).
- 12. Matthews, R. T., et al., Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. **18(1)**, 156-163 (1998).
- 13. Bergnes, G., et al., Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis. Oncol. Res., **8(3)**, 121-130 (1996).
- Wyss, M., and Kaddurah-Daouk, R., Creatine and creatinine metabolism. Physiol. Rev. 80(3), 1107-1213 (2000).

CMH/RXR 5/03